Jun 13, 2022
June 17, 2020
Gaithersburg, MD, and Vancouver, Canada – Sirnaomics Inc. (Sirnaomics) and Precision NanoSystems Inc. (PNI) jointly announced a partnership on the development and manufacture of the polypeptide nanoparticle-based RNAi therapeutic product. This strategic joint effort includes the execution of a NanoAssemblr® platform license and supply agreement, plus successful production of multiple batches of Sirnaomics drug product candidates, STP705 and STP707, for ongoing IND enabling safety and toxicity studies, as well as several clinical studies.
Sirnaomics is a clinical stage biopharmaceutical company specialized in RNAi-based therapeutics for addressing the unmet needs in treatment of cancers and fibrosis diseases. The company has developed proprietary polypeptide nanoparticle carriers for efficient siRNA delivery, to advance an enriched drug product pipeline. Sirnaomics’ lead product candidate, STP705, is an siRNA (small interfering RNA) therapeutic which takes advantage of a dual-targeted inhibitory property together with a polypeptide nanoparticle (PNP)-enhanced delivery to directly knock down both TGF-β1 and COX-2 gene expression. The product candidate has received multiple IND approvals from both the US FDA and Chinese NMPA, including treatments of Cholangiocarcinoma, Non-Melanoma skin cancer and Hypertrophic Scar. STP705 has also received Orphan Drug Designation for treatment of Cholangiocarcinoma, Primary Sclerosing Cholangitis and Hepatocellular Carcinoma. A recent interim analysis report of a phase IIa clinical study on STP705 for treatment of Squamous Cell Carcinoma in situ indicated the topline therapeutic results with complete histological clearance tumor cell on treated sites. Using the same dual targets design, Sirnaomics has further developed STP707, a systemic formulation with broader application potential.
Sirnaomics’ founder, president and CEO, Dr. Patrick Lu said, "As the leader in RNAi therapeutics specialized in polypeptide nanoparticle formulation, we are so excited to see the further advancement of our process development and large scale product manufacturing, using PNI’s NxGen™ microfluidic technology. In working with PNI’s team and the NanoAssemblr platform, we were able to establish a robust manufacturing process from a nominated drug candidate to GMP manufacturing in just a few months, greatly accelerating our drug development process”. Sirnaomics is currently using these batches produced with NxGen™ for non-human primate safety toxicity studies and clinical studies.”
PNI is a global leader in technology solutions to enable the development and manufacture of new nanomedicines in the areas of vaccines, cell therapies and gene therapies for the treatment of oncology, infectious diseases, and rare diseases. With the NanoAssemblr suite of products, PNI provides solutions across the drug development process for clients to develop and seamlessly scale their drug programs. Dr. James Taylor, co-founder and CEO of PNI said, “We are pleased to support Sirnaomics, an innovative RNAi therapeutics company, with our NanoAssemblr platform and Clinical Solutions Team that helped take their drug program to a successful GMP batch manufacture. We believe the NanoAssemblr microfluidic technology enables exquisite control over the particle size, charge and encapsulation efficiency which was important for the performance of Sirnaomics’ drug product candidates.” PNI’s NanoAssemblr platform, with over 400 systems placed worldwide, is designed to enable drug developers to rapidly progress from R&D to industrial-scale nanomedicine manufacture.
Sirnaomics, Inc., a leading privately held biopharmaceutical company for discovery and development of RNAi therapeutics, is a Delaware corporation headquartered in Gaithersburg, Maryland, USA, with subsidiaries in Suzhou and Guangzhou, China. The Company’s mission is to develop novel therapeutics to alleviate human suffering and advance patient care in areas of high unmet medical need. The guiding principles of the company are: Innovation, Global Vision with a Patient Centered focus. Members of the senior management team have a great deal of combined experience in the biopharmaceutical industry, financial, clinical and business management in both the USA and China. The company is supported by funding from institutional investors, corporate partnerships and government grants. Sirnaomics has developed a strong portfolio of intellectual property with an enriched product pipeline. The therapeutic areas of focus include oncology and anti-fibrotic therapeutics. Learn more at www.sirnaomics.com.
About Precision NanoSystems Inc.
Precision NanoSystems Inc. (PNI) proprietary NanoAssemblr Platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology. For more information visit http://www.precisionnanosystems.com.
Jun 13, 2022
Jun 14, 2017
Nanoparticles, and liposomes in particular, have been used for drug delivery in cancer and inflammatory disease therapies for several years, but traditional manufacturing methods are labor intensive, hard to reproduce, and difficult to scale up. Be...